Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 25, 2018

Multiple Ascending Dose Study of the Tau-Directed Monoclonal Antibody BIIB092 in Patients with Progressive Supranuclear Palsy (S27.004)

Adam Boxer, Irfan Qureshi, Michael Grundman, Giridhar S. Tirucherai, Clifford Bechtold, Michael Ahlijanian, Gerry Kolaitis, Lawrence I. Golbe, Lawrence S. Honig, Stuart Isaacson, Murray Grossman, Nikolaus R. McFarland, Irene Litvan, David S. Geldmacher, Tao Xie, Yvette Bordelon, Paul Tuite, Padraig O’Suilleabhain, Theresa Zesiewicz
First published April 9, 2018,
Adam Boxer
1University of California, San Francisco, CA San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irfan Qureshi
2formerly Bristol-Myers Squibb, Lawrenceville, NJ, and Wallingford, CT Lawrenceville NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Grundman
3Global R&D Partners, LLC, San Diego, CA San Diego CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giridhar S. Tirucherai
4Bristol-Myers Squibb, Lawrenceville, NJ, and Wallingford, CT Lawrenceville NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifford Bechtold
2formerly Bristol-Myers Squibb, Lawrenceville, NJ, and Wallingford, CT Lawrenceville NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Ahlijanian
4Bristol-Myers Squibb, Lawrenceville, NJ, and Wallingford, CT Lawrenceville NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerry Kolaitis
4Bristol-Myers Squibb, Lawrenceville, NJ, and Wallingford, CT Lawrenceville NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence I. Golbe
5Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ New Brunswick NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence S. Honig
6Columbia University Medical Center, New York, NY New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart Isaacson
7Boca Raton Institute for Neurodegenerative Disorders, Boca Raton, FL Boca Raton FL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murray Grossman
8University of Pennsylvania, Philadelphia, PA Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolaus R. McFarland
9University of Florida, Gainesville, FL Gainesville FL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Litvan
10University of California, San Diego, CA La Jolla CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Geldmacher
11University of Alabama at Birmingham, Birmingham, AL Birmingham AL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tao Xie
12University of Chicago, Chicago, IL Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yvette Bordelon
13University of California, Los Angeles, CA Los Angeles CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Tuite
14University of Minnesota, Minneapolis, MN Minneapolis MN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Padraig O’Suilleabhain
15University of Texas Southwestern Medical Center, Dallas, TX Dallas TX United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa Zesiewicz
16University of South Florida, Tampa, FL Tampa FL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Multiple Ascending Dose Study of the Tau-Directed Monoclonal Antibody BIIB092 in Patients with Progressive Supranuclear Palsy (S27.004)
Adam Boxer, Irfan Qureshi, Michael Grundman, Giridhar S. Tirucherai, Clifford Bechtold, Michael Ahlijanian, Gerry Kolaitis, Lawrence I. Golbe, Lawrence S. Honig, Stuart Isaacson, Murray Grossman, Nikolaus R. McFarland, Irene Litvan, David S. Geldmacher, Tao Xie, Yvette Bordelon, Paul Tuite, Padraig O’Suilleabhain, Theresa Zesiewicz
Neurology Apr 2018, 90 (15 Supplement) S27.004;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To assess the safety, tolerability, pharmacokinetic and pharmacodynamic effects of BIIB092 (formerly BMS-986168) on free extracellular tau (eTau) after every 4 week intravenous infusions (Q4W) in patients with progressive supranuclear palsy (PSP).

Background: BIIB092 is a humanized monoclonal antibody that binds to tau at the N-terminal domain. In a phase I study, single dose BIIB092 (up to 4200 mg) safely and effectively suppressed free eTau in healthy subject CSF.

Design/Methods: Randomized, double-blind, placebo-controlled, multiple ascending dose trial in 48 patients with PSP. In each cohort, BIIB092 (150 mg, 700 mg, or 2100 mg) or placebo was administered in a 3:1 ratio (n=8 patients/cohort) intravenously Q4W for 12 weeks; an additional expansion panel (24 patients) received 2100 mg or placebo Q4W for 12 weeks. After 12 weeks, completed participants were eligible for an open-label extension study. Safety assessments and serum and CSF samples were collected over 12 weeks. Pharmacokinetic parameters (serum and CSF) and absolute and percent change from baseline in pharmacodynamic measures (concentrations of CSF free eTau) were evaluated.

Results: Mean age was 67.4 ± 5.5 years; 54.2% were female. BIIB092 serum and CSF concentrations increased with dose. Mean suppression of CSF free eTau was ~90–96% (Day 29) and 91–97% (Day 85). There were no deaths or discontinuations due to AEs. The percentages of patients experiencing adverse events (AEs) were similar in the treatment and placebo groups (~75%); most were mild and unrelated to study drug.

Conclusions: Administration of multiple doses of BIIB092 was safe and well tolerated at doses up to 2100 mg in patients with PSP. The suppression of CSF free eTau concentrations in this study is consistent with target engagement in the CSF and further supports the potential utility of BIIB092 in the treatment of human tauopathies. Research is ongoing in PSP (efficacy, NCT03068468) and in development for Alzheimer’s disease.

Study Supported by:

The study was funded by Bristol-Myers Squibb, Lawrenceville, NJ, USA and Wallingford, CT, USA. Writing and editorial support for the preparation of this poster was provided by Excel Scientific Solutions (Southport, CT, USA): funding was provided by Biogen.

Disclosure: Dr. Boxer has nothing to disclose. Dr. Qureshi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BMS, Biohaven. Dr. Qureshi holds stock and/or stock options in former BMS employee: Biohaven Pharmaceutical employee. Dr. Grundman holds stock and/or stock options in Prothena Biosciences Inc., which sponsored research in which Dr. Grundman was involved as an investigator. Dr. Grundman has received research support from Prothena Biosciences Inc. Dr. Tirucherai has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of BMS. Dr. Tirucherai holds stock and/or stock options in BMS. Dr. Bechtold has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BMS. Dr. Ahlijanian has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BMS employee,. Dr. Ahlijanian has received research support from Bristol-Myers Squibb, Pinteon Therapeutics, FORMA Therapeutics. Dr. Kolaitis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BMS employee. Dr. Kolaitis holds stock and/or stock options in BMS, which sponsored research in which Dr. Kolaitis was involved as an investigator. Dr. Kolaitis holds stock and/or stock options in BMS. Dr. Golbe has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BMS, AbbVie, USB. Dr. Golbe has received research support from research funds went to university. Dr. Honig has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Miller Medical Communications (webinar presenter). Dr. Honig has received personal compensation in an editorial capacity for JAMA Neurology (assoc. ed). Dr. Isaacson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consultancy and/or promotional speaker fees: Acadia, Acorda, Adamas, Allergan, Amarantus, Biotie, Britannia, Cynapsus, GE Pharma, Impax, Ipsen, Kyowa, Lundbeck, Teva, UCB, and US WorldMeds. Research funding: AbbVie, Acadia, Acorda, Adamas, Addex, Allergan. Dr. Grossman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GE Whitney. Dr. Grossman has received personal compensation in an editorial capacity for Neurology. Dr. McFarland has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Litvan has received personal compensation for serving onthe scientific steering committee of the Biotie/Parkinson Study Group clinical trial Dr. Geldmacher has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Axovant, BrownGreer, Clearview Partners, Grifols, Pennside Partners. Dr. Geldmacher has received research support from Abbvie, Avanir, Biogen, BMS, Eisai, Janssen, Lilly, Lundbeck. Dr. Xie has nothing to disclose. Dr. Bordelon has nothing to disclose. Dr. Tuite has nothing to disclose. Dr. O'Suilleabhain has received research support from BMS. Dr Zesiewicz has nothing to disclose.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (7)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise